|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 123.34 USD | +1.64% |
|
+0.53% | +33.45% |
| 12-10 | This Is Decision Day |  |
| 12-10 | Wells Fargo Adjusts Price Target on Gilead Sciences to $150 From $145, Maintains Overweight Rating | MT |
Business description: Gilead Sciences, Inc.
- sale of drugs (99.5%): for the treatment of HIV (68.5% of net sales), oncology diseases (11.5%), hepatitis B virus (10.6%), Ebola virus (6.3%) and other (3.1%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (0.5%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (71.6%), Europe (16.1%) and other (12.3%).
Number of employees: 17,600
Sales by Activity: Gilead Sciences, Inc.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
Discovery, Development and Commercialization of Innovative Medicines | 24.69B | 27.3B | 27.28B | 27.12B | 28.75B |
Geographical breakdown of sales: Gilead Sciences, Inc.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
United States | 18.22B | 19.27B | 18.88B | 19.44B | 20.59B |
Europe | 4.14B | 4.87B | 4.47B | 4.31B | 4.63B |
Rest of World | 2.34B | 3.16B | 3.93B | 3.37B | 3.53B |
Executive Committee: Gilead Sciences, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 60 | 28/02/2019 |
Andrew Dickinson
DFI | Director of Finance/CFO | 55 | 31/10/2019 |
Dietmar Berger
CTO | Chief Tech/Sci/R&D Officer | 63 | 01/01/2025 |
Jacquie Ross
IRC | Investor Relations Contact | - | 31/12/2020 |
Robert Cook
PRN | Corporate Officer/Principal | 66 | 29/02/2012 |
Composition of the Board of Directors: Gilead Sciences, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Kelly Kramer
BRD | Director/Board Member | 57 | 18/08/2016 |
| Director/Board Member | 72 | 31/12/2017 | |
| Director/Board Member | 71 | 08/05/2018 | |
Daniel O'Day
CHM | Chairman | 60 | 28/02/2019 |
Sandra Horning
BRD | Director/Board Member | 76 | 27/01/2020 |
Javier Rodriguez
BRD | Director/Board Member | 54 | 14/06/2020 |
Anthony Welters
BRD | Director/Board Member | 70 | 16/10/2020 |
| Director/Board Member | 71 | 06/12/2020 | |
Ted Love
BRD | Director/Board Member | 66 | 31/01/2024 |
Holdings: Gilead Sciences, Inc.
| Name | Equities | % | Valuation |
|---|---|---|---|
ARCUS BIOSCIENCES, INC. 25.4% | 31,424,760 | 25.4% | 820,186,236 $ |
GALAPAGOS NV 25.35% | 16,707,477 | 25.35% | 524,301,847 $ |
ARCELLX, INC. 11.62% | 6,720,803 | 11.62% | 488,669,586 $ |
ASSEMBLY BIOSCIENCES, INC. 28.95% | 4,505,391 | 28.95% | 170,258,726 $ |
TANGO THERAPEUTICS, INC. 4.36% | 4,854,443 | 4.36% | 52,961,973 $ |
MERUS N.V. 0.6% | 452,527 | 0.6% | 43,505,946 $ |
| 4,126,119 | 9.42% | 31,647,333 $ | |
| 5,319,148 | 9.39% | 8,138,296 $ | |
XILIO THERAPEUTICS, INC. 17.34% | 9,105,451 | 17.34% | 6,901,932 $ |
Company details: Gilead Sciences, Inc.
Group companies: Gilead Sciences, Inc.
| Name | Category and Sector |
|---|---|
Gilead Sciences Ireland UC
 Gilead Sciences Ireland UC Engages in discover, develops and deliver innovative therapeutics for life-threatening diseases | |
Gilead Sciences Ireland UC
Gilead Sciences Ireland UC Engages in discover, develops and deliver innovative therapeutics for life-threatening diseases | |
Gilead Therapeutics A1 Unlimited Co.
 Gilead Therapeutics A1 Unlimited Co. Develops and manufactures pharmaceutical medicines |
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.64% | +0.53% | +33.43% | +39.22% | 151B | |
| +2.61% | +0.39% | +27.94% | +177.32% | 890B | |
| +1.85% | +3.74% | +43.25% | +18.12% | 498B | |
| -0.97% | -2.59% | +27.76% | +34.76% | 398B | |
| -1.27% | +2.52% | +24.23% | +4.92% | 343B | |
| +0.61% | +0.61% | +29.02% | +19.79% | 279B | |
| +0.53% | -0.84% | +20.51% | +24.79% | 252B | |
| +1.29% | -2.05% | -0.93% | -9.31% | 242B | |
| +3.43% | +4.55% | -59.55% | -29.95% | 214B | |
| +0.49% | -6.77% | +15.99% | +14.58% | 170B | |
| Average | +1.04% | -2.05% | +16.17% | +29.42% | 343.63B | |
| Weighted average by Cap. | +1.22% | -1.92% | +21.47% | +56.39% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GILD Stock
- Company Gilead Sciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition